Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fortress Biotech

1.77
+0.04502.62%
Mar 25 14:47 EST
Volume:251.81K
Turnover:433.99K
Market Cap:48.72M
PE:-0.52
High:1.78
Open:1.73
Low:1.68
Close:1.72
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
Loading ...

Checkpoint Therapeutics Inc Qtrly Shr Loss $0.23

THOMSON REUTERS
·
12 Nov 2024

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

THOMSON REUTERS
·
12 Nov 2024

Press Release: Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Dow Jones
·
12 Nov 2024

Press Release: Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Dow Jones
·
12 Nov 2024

Mustang Bio Inc - Extension Granted to Meet $1.00 Bid Price Requirement Through Jan 31, 2025

THOMSON REUTERS
·
12 Nov 2024

Mustang Bio Receives Positive Listing Determination From Nasdaq

THOMSON REUTERS
·
12 Nov 2024

Checkpoint Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Avenue Therapeutics Inc expected to post a loss of 94 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Fortress Biotech Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Mustang Bio - Mb-108 (Hsv-1 Oncolytic Virus) Is Active and Well Tolerated in Patients With Recurrent Glioblastoma in Ongoing Phase 1 Clinical Trial

THOMSON REUTERS
·
07 Nov 2024

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for Mb-108 (Hsv-1 Oncolytic Virus) to Treat Malignant Glioma

THOMSON REUTERS
·
07 Nov 2024

FDA approves Journey Medical's drug for long-term skin condition

Reuters
·
04 Nov 2024

Journey Medical Corp - Initial Supply of Emrosi Expected in Q1 or Q2 2025

THOMSON REUTERS
·
04 Nov 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 Mg) for the Treatment of Rosacea

THOMSON REUTERS
·
04 Nov 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

GlobeNewswire
·
04 Nov 2024

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m

Simply Wall St.
·
31 Oct 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."